HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogel, W. Articles by Brugger, W. Search for Related Content PubMed PubMed Citation Articles by Vogel, W. Articles by Brugger, W.

Clinical Applications of CD34⁺ Peripheral Blood Progenitor Cells (PBPC)

Department of Hematology, Oncology, Rheumatology and Immunology, Medical Center II, Eberhard-Karls-University, Tübingen, Germany

Key Words. CD34⁺ • Selection technologies • Autologous • Allogeneic • Transplantation

Wolfram Brugger, M.D., Department of Medicine, Otfried-Müller-Str. 10,72076 Tübingen, Germany. Telephone: 49-7071-2983698; Fax: 49-7071-295591; e-mail:wolfram.brugger{at}med.uni-tuebingen.de

Recently, a number of devices have been developed for the positive selection of CD34⁺ peripheral blood progenitor cells (PBPC) for clinical use in autologous or allogeneic transplantation. The rationale for CD34⁺ selection is based on clinical studies showing a two- to five-log reduction of contaminating tumor cells in patients with breast cancer, multiple myeloma and low-grade lymphoma. In addition, a three- to five-log reduction of T cells can be obtained by CD34⁺ selection in both autologous grafts for patients with autoimmune disease resistant to conventional therapy and allogeneic grafts to reduce the incidence and severity of acute graft-versus-host disease.

Transplantation of positively selected autologous CD34⁺ PBPC results in a rapid and stable neutrophil and platelet engraftment in patients who received an infused dose of at least 2.0 x 10⁶ CD34⁺ cells/kg. Results from randomized trials suggest that time to engraftment is not different compared to unmanipulated PBPC autografts. However, close monitoring for infectious complications (e.g., cytomegalovirus disease) is required. Allogeneic CD34⁺ PBPC have also been successfully transplanted and, using novel technologies, megadoses of purified CD34⁺ PBPC can be obtained and used to overcome histocompatibility differences betweeen allogeneic donor and patient resulting in stable engraftment, even in a haploidentical setting. Additional randomized phase III trials are required to determine whether tumor cell purging or lymphocyte depletion by CD34⁺ cell selection will have a significant impact on progression-free and overall survival in both autologous and allogeneic transplantation.

This article has been cited by other articles:

				K. Leibundgut, N. M.R. Schmitz, and A. Hirt Catalytic Activities of G1 Cyclin-Dependent Kinases and Phosphorylation of Retinoblastoma Protein in Mobilized Peripheral Blood CD34+ Hematopoietic Progenitor Cells Stem Cells, August 1, 2005; 23(7): 1002 - 1011. [Abstract] [Full Text] [PDF]

				W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, W. Vogel, H.-G. Kopp, M. G. Manz, M. Bitzer, G. Schlimok, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study Ann. Onc., November 1, 2004; 15(11): 1691 - 1698. [Abstract] [Full Text] [PDF]

				J. Wang, T. Kimura, R. Asada, S. Harada, S. Yokota, Y. Kawamoto, Y. Fujimura, T. Tsuji, S. Ikehara, and Y. Sonoda SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection Blood, April 15, 2003; 101(8): 2924 - 2931. [Abstract] [Full Text] [PDF]

				C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle Side effects of retroviral gene transfer into hematopoietic stem cells Blood, March 15, 2003; 101(6): 2099 - 2113. [Abstract] [Full Text] [PDF]

				G. B. Adams, K. T. Chabner, R. B. Foxall, K. W. Weibrecht, N. P. Rodrigues, D. Dombkowski, R. Fallon, M. C. Poznansky, and D. T. Scadden Heterologous cells cooperate to augment stem cell migration, homing, and engraftment Blood, January 1, 2003; 101(1): 45 - 51. [Abstract] [Full Text] [PDF]

				M. E. Merino, F. Navid, B. L. Christensen, J. A. Toretsky, L. J. Helman, N.-K. V. Cheung, and C. L. Mackall Immunomagnetic Purging of Ewing's Sarcoma From Blood and Bone Marrow: Quantitation by Real-Time Polymerase Chain Reaction J. Clin. Oncol., August 15, 2001; 19(16): 3649 - 3659. [Abstract] [Full Text] [PDF]